Market capitalization | $952.16m |
Enterprise Value | $750.48m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 48.08 |
P/S ratio (TTM) P/S ratio | 61.00 |
P/B ratio (TTM) P/B ratio | 8.61 |
Revenue growth (TTM) Revenue growth | -14.78% |
Revenue (TTM) Revenue | $15.61m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
10 Analysts have issued a Liquidia Technologies, Inc. forecast:
10 Analysts have issued a Liquidia Technologies, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 16 16 |
15%
15%
|
|
Gross Profit | 8.94 8.94 |
37%
37%
|
|
EBITDA | -109 -109 |
115%
115%
|
EBIT (Operating Income) EBIT | -112 -112 |
109%
109%
|
Net Profit | -119 -119 |
107%
107%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.
Head office | United States |
CEO | Roger Jeffs |
Employees | 136 |
Founded | 2004 |
Website | www.liquidia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.